Based on real-world data, the combination of EGFR-TKI and Crizotinib in patients with EGFRm+ NSCLC progressing on EGFR-TKIs due to acquired MET amplification is feasible and currently a reasonable option while we are awaiting the results of clinical trials with new, more potent MET inhibitors. Here, MET is linked to non-small cell lung carcinoma.